

# The Role of Hindbrain GABA-ergic Signaling in the Modulation of Anorexia and Malaise




Xing (Serena) Gao<sup>1,2</sup>, C. Daniel Furst<sup>2</sup>, Julia Halas<sup>2</sup>, Allison Pataro<sup>2</sup>, Bart C. De Jonghe<sup>2,3</sup>, Tito Borner<sup>2,3</sup>

<sup>1</sup> School of Arts and Sciences, Class of 2023, University of Pennsylvania, Philadelphia, PA

<sup>2</sup> Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA

<sup>3</sup> Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA




## Introduction

**Nausea and vomiting** are two of the most distressing side effects in treatments for diseases such as diabetes, obesity, and cancer which often leads to **poor quality of life and treatment discontinuation**.

Emesis and nausea are largely controlled by the central nervous system (CNS), specifically by the **area postrema (AP)** and the **nucleus of the solitary tract (NTS)**, two adjacent hindbrain nuclei.

Recent work from our lab has shown that glucose-dependent insulinotropic polypeptide receptor (**GIPR**) agonism reduces the occurrence of nausea and emesis induced by Glucagon-like peptide 1 (**GLP-1**) based therapeutics.

A high percentage of the GIPR expressing neurons co-express the **inhibitory neurotransmitter GABA** (*Gad2*) in the AP/NTS, suggesting that GIPR agonism may exert its anti-emetic effects by indirectly inhibiting emetic AP/NTS neurons, through increasing local GABA release.



**Fig.1: Working model:** GIPR activation may counteract GLP-1/chemotherapy-induced malaise via direct modulation of the AP/NTS circuitry. Given the inhibitory nature of the GIPR-expressing neurons, one can speculate the existence of a local inhibitory network within the caudal hindbrain that could be exploited via GIPR activation to reduce hindbrain GLP-1R-mediated emesis and nausea.


## Methods and Aims

By performing AP/NTS-targeted injections of adeno-associated viruses (AAVs) which cre-dependently encode for excitatory ( $G_q$ -coupled) designer receptors exclusively activated by designer drugs (DREADDs) in the *Gad-cre* rats, this study aims at:

1. Determine whether chemogenetic activation of *Gad*<sup>+</sup> neurons in the AP/NTS attenuates Semaglutide-induced malaise in rats.
2. Test if chemogenetic activation of *Gad*<sup>+</sup> neurons in the AP/NTS attenuates malaise induced by the chemotherapeutic agent cisplatin in rats.
3. Evaluate the effects of chemogenetic activation of *Gad*<sup>+</sup> neurons in the AP/NTS on gastric emptying in rats.
4. Quantify in vivo co-localization of cFos expression induced by the chemotherapeutic agent cisplatin and chemogenetic activation of *Gad*<sup>+</sup> neurons in the AP/NTS in rats.


## Results

### Activation of AP/NTS GABA-ergic neurons enhances semaglutide-induced hypophagia while reducing malaise




**Fig.1: (A)** CNO-induced (1mg/kg IP) activation of AP/NTS GABA-ergic neurons alone induces anorexia. When CNO is combined with semaglutide (5nmol/kg IP), the treatment results in a more profound anorexia in rats than semaglutide alone. **(B)** Compared to semaglutide administration, the combined treatment reduced pica behavior (the consumption of non-nutritive kaolin clay, a well validated a proxy for nausea in animals that, like rodents, lack the emetic reflex). **(C)** Both combined treatment and semaglutide treatment cause reduction in body weight 24h post injection. The suppression of food intake and reduced pica suggests that GABA-ergic signaling within the AP/NTS can inhibit emesis/nausea without reducing the ability of semaglutide to reduce feeding. All Data analyzed with repeated measurements 2-way ANOVAs followed by Tukey post hoc test. Data expressed as mean  $\pm$  SEM. Means with different letters are significantly different from each other ( $P < 0.05$ ).

### Enhancing AP/NTS GABA-ergic signaling reduces malaise induced by cisplatin while enhancing hypophagia




**Fig.2: (A)** Both cisplatin (6 mg/kg IP) and CNO (1mg/kg IP) induced anorexia. **(B)** Remarkably, CNO treatment reduced pica behavior induced by cisplatin. **(C)** Activation of GABA-ergic neuron caused further weight loss when combined with cisplatin. The reduced pica suggests that inhibitory GABA signaling within the AP/NTS can inhibit emesis/nausea induced by chemotherapeutic agent cisplatin but it also aggravates the anorectic effects of cisplatin. All Data analyzed with repeated measurements 2-way ANOVAs followed by Tukey post hoc test. Data expressed as mean  $\pm$  SEM. Means with different letters are significantly different from each other ( $P < 0.05$ ).

### Validation of chemogenetic tools for selective activation of AP/NTS GABA-ergic neurons and evaluation of AP/NTS neuronal activation following cisplatin treatment



**Fig.3: (A)** Representative image of the AP/NTS using the nuclear staining DAPI (blue) in *Gad-cre* rats. **(B)** Representative image depicting the spread and intensity of the expression of the excitatory DREADD (*Gq*) (red). **(C)** Representative immunofluorescent images showing neuronal activation (*c-Fos* expression; green) in the AP/NTS 24h after CNO (1mg/kg IP) and Cisplatin (6mg/kg IP) combination treatment. Quantification of *c-Fos*<sup>+</sup> neurons in the caudal NTS and in the AP are still ongoing. (Scale bar: 100 $\mu$ m).

### Activation of AP/NTS GABA-ergic neurons delays gastric emptying



**Fig.4: (A)** Changes in circulating paracetamol levels (i.e., a validated proxy for gastric emptying) in response to CNO-induced (1mg/kg IP) activation of AP/NTS GABA-ergic neurons were measured at 0, 30, 60, and 90 min following administration of a liquid meal containing 40mg paracetamol ( $n = 8$  per group). **(B)** Paracetamol AUC from 0 to 90 min after treatment. **(C-D)** Blood paracetamol concentrations of the CNO group at 30 min after the administration of the liquid meal was significantly lower than the control group. All data are expressed as mean  $\pm$  SEM. Data in A were analyzed with repeated-measurements 2-way ANOVA, followed by the Sidak post hoc test. Data in B-D were analyzed with paired *t*-test. Means with different letters are significantly different from each other ( $P < 0.05$ ).

## Conclusions

Activation of AP/NTS GABA-ergic neurons attenuated both semaglutide-induced and cisplatin-induced malaise and also increased their hypophagic effects, partially via delayed gastric emptying.

Our results point to a key role of GABA-ergic neurons as understudied modulators of feeding and illness-like behaviors and provide a neuroanatomical and mechanistic explanation for the anti-emetic effects of GIPR agonisms.

## Acknowledgement

This work was supported by the Goldfeder Family Undergraduate Research Grant.